VANCOUVER, British Columbia — Four of 29 Eylea kit lots were associated with 62% of cases of sterile intraocular inflammation following injection that were reported to the American Society of Retina Specialists Research and Safety in Therapeutics Committee, according to the results of a retrospective study.
The review included 92 eyes of 88 patients who experienced inflammation after an Eylea (aflibercept, Regeneron) injection and were voluntarily reported to ASRS by 15 practices throughout the United States from Jan. 7, 2017, to Jan. 19, 2018.
“With regard to clustering of cases,
Uncategorized